Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial.

MLA

Dieci, Maria Vittoria, et al. “Type of Adjuvant Endocrine Therapy and Disease-Free Survival in Patients with Early HR-Positive/HER2-Positive BC: Analysis from the Phase III Randomized ShortHER Trial.” NPJ Breast Cancer, vol. 9, no. 1, Feb. 2023, p. 6. EBSCOhost, https://doi.org/10.1038/s41523-023-00509-2.

APA

Dieci, M. V., Bisagni, G., Bartolini, S., Frassoldati, A., Vicini, R., Balduzzi, S., D’amico, R., Conte, P., & Guarneri, V. (2023). Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial. NPJ Breast Cancer, 9(1), 6. https://doi.org/10.1038/s41523-023-00509-2

Chicago

Dieci, Maria Vittoria, Giancarlo Bisagni, Stefania Bartolini, Antonio Frassoldati, Roberto Vicini, Sara Balduzzi, Roberto D’amico, Pierfranco Conte, and Valentina Guarneri. 2023. “Type of Adjuvant Endocrine Therapy and Disease-Free Survival in Patients with Early HR-Positive/HER2-Positive BC: Analysis from the Phase III Randomized ShortHER Trial.” NPJ Breast Cancer 9 (1): 6. doi:10.1038/s41523-023-00509-2.